Genmab A/S Stock Nasdaq
Stocks
GMAB
US3723032062
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Nasdaq
04:00:00 2026-11-06 pm EST
|
5-day change | 1st Jan Change | ||
| 53.63 USD | +1.69% |
|
-6.01% | +74.12% |
| Nov. 06 | Genmab: Strong profit beat but guidance unchanged; time to book profits |  |
| Nov. 06 | Goldman Sachs raises price target for Genmab to DKK4,500 (4,450), reiterates buy - BN | FW |
| Market Cap | 223B 33.29B 29.86B 27.29B 24.91B 46.94B 3,130B 48.42B 329B 131B 1,670B 125B 122B 5,272B | P/E 2026 * |
42.3x | P/E 2027 * | 31.1x |
|---|---|---|---|---|---|
| Enterprise Value | 242B 36.05B 32.33B 29.55B 26.98B 50.82B 3,389B 52.43B 356B 142B 1,808B 135B 132B 5,708B | EV / Sales 2026 * |
8.06x | EV / Sales 2027 * | 6.47x |
| Free-Float |
94.3% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| GMAB | Delayed | |
CBOE
| GMAB | Real-time | |
|
Börse Stuttgart
| GE91 | Delayed | |
|
Tradegate
| GE91 | Real-time | |
|
Deutsche Boerse AG
| GE91 | Delayed | |
|
Boerse Muenchen
| GE91 | Real-time |
Last Transcript: Genmab A/S
| 1 day | +1.69% | ||
| 1 week | -6.01% | ||
| Current month | -6.01% | ||
| 1 month | +46.33% | ||
| 3 months | +71.62% | ||
| 6 months | +98.19% | ||
| Current year | +74.12% |
| 1 week | 51.22 |  | 56.84 |
| 1 month | 36.12 | | 59.97 |
| Current year | 23.62 | | 59.97 |
| 1 year | 23.62 | | 59.97 |
| 3 years | 17.24 | | 59.97 |
| 5 years | 17.24 | | 59.97 |
| 10 years | 12.1 | | 59.97 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2010-05-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 2020-02-29 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 2024-08-15 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 2003-10-31 | |
| Director/Board Member | 58 | 2014-12-31 | |
| Director/Board Member | 75 | 2014-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.69% | -6.01% | - | - | 33.29B | |
| -4.83% | +3.51% | +55.00% | +63.79% | 65.94B | |
| +0.02% | +1.07% | +11.72% | +75.63% | 56.88B | |
| -1.34% | +2.98% | +25.08% | +100.18% | 56.53B | |
| +5.09% | +9.89% | +27.19% | +105.85% | 46.49B | |
| +2.62% | +1.68% | +29.16% | +35.86% | 44.8B | |
| +8.24% | +0.51% | +215.16% | +794.74% | 41.59B | |
| -1.86% | +10.13% | +28.14% | +55.48% | 35.35B | |
| -2.97% | -9.84% | +90.91% | +73.49% | 33.29B | |
| +5.19% | +1.62% | -39.69% | +368.87% | 25.1B | |
| Average | +1.19% | +2.65% | +49.18% | +185.99% | 45.11B | |
| Weighted average by Cap. | +0.74% | +3.07% | +49.89% | +166.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 29.99B 4.47B 4.01B 3.67B 3.35B 6.3B 420B 6.5B 44.19B 17.62B 224B 16.79B 16.43B 708B | 36.26B 5.41B 4.85B 4.43B 4.05B 7.62B 508B 7.86B 53.43B 21.31B 271B 20.3B 19.86B 856B |
| Net income | 5.14B 766M 687M 628M 573M 1.08B 72.02B 1.11B 7.57B 3.02B 38.43B 2.88B 2.81B 121B | 7.73B 1.15B 1.03B 945M 862M 1.62B 108B 1.68B 11.39B 4.54B 57.81B 4.33B 4.23B 182B |
| Net Debt | 18.49B 2.76B 2.47B 2.26B 2.06B 3.89B 259B 4.01B 27.24B 10.86B 138B 10.35B 10.13B 437B | 11.29B 1.68B 1.51B 1.38B 1.26B 2.37B 158B 2.45B 16.63B 6.63B 84.43B 6.32B 6.18B 267B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-06 | $53.63 | +1.69% | 7,828,333 |
| 26-11-05 | $52.74 | -4.32% | 4,400,181 |
| 26-11-04 | $55.12 | -0.72% | 4,299,450 |
| 26-11-03 | $55.52 | +1.09% | 3,060,842 |
| 26-11-02 | $54.92 | -3.75% | 4,424,670 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
Select your edition
All financial news and data tailored to specific country editions
